Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jaguar Health (JAGX) Cash from Financing Activities (2016 - 2025)

Jaguar Health (JAGX) has disclosed Cash from Financing Activities for 11 consecutive years, with $6.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Financing Activities rose 77.31% to $6.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $16.7 million, a 57.18% decrease, with the full-year FY2024 number at $31.2 million, down 8.84% from a year prior.
  • Cash from Financing Activities was $6.3 million for Q3 2025 at Jaguar Health, up from $2.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $30.9 million in Q1 2021 to a low of $373000.0 in Q3 2021.
  • A 5-year average of $7.7 million and a median of $5.0 million in 2025 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: soared 2620.38% in 2022, then crashed 86.11% in 2023.
  • Jaguar Health's Cash from Financing Activities stood at $3.1 million in 2021, then tumbled by 47.52% to $1.6 million in 2022, then skyrocketed by 550.18% to $10.6 million in 2023, then tumbled by 73.43% to $2.8 million in 2024, then soared by 121.17% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's Cash from Financing Activities are $6.3 million (Q3 2025), $2.7 million (Q2 2025), and $5.0 million (Q1 2025).